naloxone

<http://www.wikidata.org/entity/Q282902>

opioid receptor antagonist
rdfs:label
"naloxone"@en
skos:altLabel
"Naloxone"@en
"(-)-naloxone"@en
"(−)-naloxone"@en
"1-N-Allyl-14-hydroxynordihydromorphinone"@en
"17-allyl-3,14-dihydroxy-4,5alpha-epoxymorphinan-6-one"@en
"17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one"@en
"l-naloxone"@en
"Nalossone"@en
"Naloxona"@en
"Naloxonum"@en
"Narcan®"@en
schema:description
"opioid receptor antagonist"@en
schema:dateModified "2026-07-14T14:11:04+00:00"^^xsd:dateTime
schema:version 2517412060
wikibase:identifiers 52
wikibase:sitelinks 43
wikibase:statements 81
p:P10245 wd:statement/Q282902-6c913c83-499f-79df-378a-5c35d1994196
wd:statement/Q282902-f89db277-4c78-b437-3491-bf049d599fe9
p:P10283 wd:statement/Q282902-140B9A2B-AD19-4901-8583-364DD3B1BA13
p:P11089 wd:statement/Q282902-573FA23F-EA56-4919-8177-2BCA59C627E1
p:P11143 wd:statement/Q282902-271F86F2-8FF4-405D-A676-B4A6E1473A73
p:P11198 wd:statement/Q282902-EBC0209B-93D0-466D-8EF4-FCCB11EAD26E
p:P11199 wd:statement/Q282902-DD2B60C9-70A5-4BA0-B66B-C13C2C3771A3
p:P117 wd:statement/Q282902-b172fbca-43de-ffe3-b1c4-5b1cb1bbcf92
p:P12385 wd:statement/Q282902-4084831d-8804-459c-b8d4-600901351ad0
p:P129 wd:statement/Q282902-B48D0F19-5A82-4217-94D6-8B88E5947B12
p:P1296 wd:statement/Q282902-293C5EB7-C4D5-4E72-BFED-5E32D5537C79
p:P1579 wd:statement/Q282902-B962EB0C-29DB-4CE8-A56B-02ED3D3A061F
p:P1889 wd:statement/Q282902-940BC956-7EA2-4C49-A6D7-F366D73452DB
p:P2017 wd:statement/Q282902-69382D5D-772C-468A-B9F8-89AC05A66F78
p:P2057 wd:statement/Q282902-3930251E-7505-4646-AB3A-C46075E9DCB8
p:P2062 wd:statement/Q282902-E32542CE-662F-4C42-AE58-132872943299
p:P2067 wd:statement/Q282902-9384A9E9-873E-484F-8A0B-DD68ADEFB460
p:P2115 wd:statement/Q282902-E7ADC13B-D6D7-4ABB-A653-971F804EDF3F
p:P2175 wd:statement/Q282902-19fe50a0-4d5b-d65f-51fd-bfcd73058907
wd:statement/Q282902-B8693CD5-B567-484A-938D-03631716D218
wd:statement/Q282902-D5B88397-920F-462E-80D3-0E48A24C2BD4
p:P2275 wd:statement/Q282902-41311342-0811-48C9-9570-A3218AB9AD20
wd:statement/Q282902-8d007b11-46b2-027d-2ef2-ff62ae396594
p:P231 wd:statement/Q282902-36BAA613-D91F-44D4-BAE9-5C3565FEFB90
p:P232 wd:statement/Q282902-705F165C-D501-43DE-84C1-0E2C41C41ACF
p:P233 wd:statement/Q282902-B24666A1-EBAF-400D-AC32-B0E6EB93AA76
p:P234 wd:statement/Q282902-621F60AE-DC82-4EDD-85F8-3BE50BDB7156
p:P2347 wd:statement/Q282902-14B70FBE-D84D-40F8-B794-4A83C11B1354
p:P235 wd:statement/Q282902-A185E020-51A8-4D6E-9F81-23015A6724DB
p:P2566 wd:statement/Q282902-13572468-2468-1357-eca9-bdf024681357
p:P267 wd:statement/Q282902-662fb67c-4af2-2620-2f91-5c6b421eb223
wd:statement/Q282902-9DA76352-F321-44EE-8FAB-38BAAB136D32
p:P274 wd:statement/Q282902-D5DF0EB2-20F7-4360-A5BB-ECC6DACD2A6E
p:P279 wd:statement/Q282902-FBAA0AAC-B6C7-44D0-A0B0-97F161C007BD
p:P2840 wd:statement/Q282902-C8279FFA-2D0B-4764-A286-E1FE2BB0CF38
p:P2868 wd:statement/Q282902-221F20AB-CA1F-4972-A99C-BFE6ACD512D3
wd:statement/Q282902-3BA9BAF2-7B2D-46C3-950B-949772DF6089
wd:statement/Q282902-F410F563-6E6A-4584-92D2-D786269F9563
p:P2877 wd:statement/Q282902-3BCA8EE5-640E-41E9-A44F-72EAB5469EC6
p:P2892 wd:statement/Q282902-97A3A3C7-4533-4C7F-87CD-1071F40F029E
p:P31 wd:statement/Q282902-B19C00D1-AD44-47CE-911D-7FEA5D0CA05C
p:P3117 wd:statement/Q282902-99516848-E89D-4963-88EC-B72F4177EC8C
p:P3345 wd:statement/Q282902-C9E748BC-CEBA-44E3-8215-59EE097FB10E
p:P3350 wd:statement/Q282902-26839e26-44c5-242e-b474-41fad51e61dc
p:P3364 wd:statement/Q282902-512F0906-3F14-427B-BC13-98CA377A1138
wd:statement/Q282902-76AC50FC-B3A9-45B3-8AE5-EBD1C64341A6
p:P3417 wd:statement/Q282902-504EF9B8-9D9D-4B09-B5EC-0DB7EA14C346
p:P3489 wd:statement/Q282902-2E13DF97-5B8B-4D39-9BF0-122315297AC3
wd:statement/Q282902-4262B137-FA91-4BB7-BE5A-250817503A7E
p:P366 wd:statement/Q282902-F67135DD-DC3E-4BBA-A052-AC7CF744D441
p:P373 wd:statement/q282902-CF9896EB-4995-42DE-9F1D-A79AD740C44D
p:P3780 wd:statement/Q282902-48C78A9D-01A7-4A9B-BD8F-E55F4AB1F47E
wd:statement/Q282902-5BF3B145-4A2E-483A-8B0E-97A7835D113E
p:P4168 wd:statement/Q282902-2458AE57-6E27-4544-8042-099C981D8128
p:P4527 wd:statement/Q282902-A949E479-9521-4AD9-9A08-87285C5345C4
p:P486 wd:statement/Q282902-696D05A0-B329-401E-B323-4B76DF72FDFF
p:P5076 wd:statement/Q282902-0EF02369-2CD8-4417-BB48-5E7940D70076
p:P5806 wd:statement/Q282902-36F0B2E6-1B8E-4AB3-96F3-B1E858F42836
p:P592 wd:statement/Q282902-7331DD96-45F6-441E-8B97-103E6EAECEF0
p:P595 wd:statement/Q282902-9FE09422-B719-445B-A730-B4F916EEABA4
wd:statement/Q282902-D704E6BF-5F3F-4990-BCE7-DAF7A8B9B079
p:P636 wd:statement/Q282902-833e2803-4115-f2b4-ada7-18eebc233f96
wd:statement/Q282902-96ca40d3-4298-129d-9d07-8f668bd15c4a
wd:statement/Q282902-f2bc4d1f-47b7-7eee-8bd2-f32d3295cff0
p:P646 wd:statement/Q282902-F183482C-20FF-432D-BA67-26F2F280C7AD
p:P652 wd:statement/Q282902-67DA2061-C34A-4FF8-AE4D-93D36D9830B6
p:P661 wd:statement/Q282902-48411F81-1177-4B15-A020-12BD47FA5300
p:P662 wd:statement/Q282902-EA11BB5F-DFC4-47DC-A901-CB396C66CF55
p:P665 wd:statement/Q282902-43218E9D-F6C4-4FCA-BBE7-FF8DC51D9972
wd:statement/Q282902-8FE4E8FD-8A8E-4CE3-9326-7BA05FA07672
p:P6694 wd:statement/Q282902-35637fdd-403f-4403-5b35-a7bb1cb422a3
p:P672 wd:statement/Q282902-216f4817-4a10-dc7a-0422-4e4c830f62f0
wd:statement/Q282902-7dfa4a14-4a77-58fe-406f-cfa993b592b1
wd:statement/Q282902-862607b5-4605-985e-d928-5e9b4b2673a8
wd:statement/Q282902-fac226c2-4944-1962-2fd5-2fbdde65137f
p:P683 wd:statement/Q282902-0481C947-EE01-4DE7-B553-3A41BA45C023
p:P703 wd:statement/Q282902-116CD62C-E5E3-4B90-9A76-0FC86CF9162B
p:P715 wd:statement/Q282902-985E9805-A1B3-4AA6-9874-6DB652903C0F
p:P8494 wd:statement/Q282902-51A43BAC-4B0B-4DD3-A6A5-C1D3B55C9BA5
p:P8814 wd:statement/Q282902-FFFDCDF7-3E16-41AE-8C7E-F05F9C831A8C
p:P9635 wd:statement/Q282902-21AB9447-8854-45ED-994F-9F441685573C
p:direct-normalized/P2115 <http://purl.bioontology.org/ontology/NDFRT/N0000147938>
p:direct-normalized/P2347 <http://www.yso.fi/onto/yso/p25987>
p:direct-normalized/P4527 <http://data.parliament.uk/terms/429795>
p:direct-normalized/P486 <http://id.nlm.nih.gov/mesh/D009270>
p:direct-normalized/P5806 <http://snomed.info/id/372890007>
p:direct-normalized/P592 <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL80>
p:direct-normalized/P661 <http://rdf.chemspider.com/4447644>
p:direct-normalized/P662 <http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284596>
p:direct-normalized/P665 <http://www.kegg.jp/entry/C07252>
<http://www.kegg.jp/entry/D08249>
p:direct-normalized/P6694 <http://id.nlm.nih.gov/mesh/M0014441>
p:direct-normalized/P672 <http://id.nlm.nih.gov/mesh/D03.132.577.249.706>
<http://id.nlm.nih.gov/mesh/D03.605.497.750>
<http://id.nlm.nih.gov/mesh/D03.633.400.686.750>
<http://id.nlm.nih.gov/mesh/D04.615.723.795.706>
p:direct-normalized/P683 <http://purl.obolibrary.org/obo/CHEBI_7459>
p:direct-normalized/P8814 <http://wordnet-rdf.princeton.edu/rdf/id/03811921-n>
wdt:P10245 "a612022"
"a616003"
wdt:P10283 "C2908806481"
wdt:P11089 "342444"
wdt:P11143 "Naloxone"
wdt:P11198 "1878"
wdt:P11199 "PD009757"
wdt:P117 <http://commons.wikimedia.org/wiki/Special:FilePath/Naloxone.svg>
wdt:P12385 "naloxona"
wdt:P129 opioidni receptor µ-1
wdt:P1296 "0125559"
wdt:P1579 "1089071"
wdt:P1889 納曲酮
wdt:P2017 "C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O"
wdt:P2057 "HMDB0015314"
wdt:P2062 "3279"
wdt:P2067 327.147^^xsd:decimal
wdt:P2115 "N0000147938"
wdt:P2175 септический шок
Overdosis opioid
Opioidberoende
wdt:P2275
"naloxone"@en
wdt:P231 "465-65-6"
wdt:P232 "207-365-7"
wdt:P233 "C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O"
wdt:P234 "InChI=1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1"
wdt:P2347 "25987"
wdt:P235 "UZHSEJADLWPNLE-GRGSLBFTSA-N"
wdt:P2566 "100.006.697"
wdt:P267 "A06AH04"
"V03AB15"
wdt:P274 "C₁₉H₂₁NO₄"
wdt:P279 alcaloid morfinan
wdt:P2840 "70413"
wdt:P2868 WHO Melecina esencial
antidot
Opioidiantagonisti
wdt:P2877 "34284"
wdt:P2892 "C0027358"
wdt:P31 رسایٚن وجودٕچ قٕسٕم
wdt:P3117 "DTXSID8023349"
wdt:P3345 "7242"
wdt:P3350 "1526"
wdt:P3364 (+)-Nalokson
(+)-naloxone
wdt:P3417 "Naloxone"
wdt:P3489 հղիության B1 կատեգորիա (Ավստրալիա)
یوٗ ایس بیٚیہِ زُو زٲژ سی
wdt:P366 zāles
wdt:P373 "Naloxone"
wdt:P3780 Evzio
Narcan
wdt:P4168 "549277"
wdt:P4527 "429795"
wdt:P486 "D009270"
wdt:P5076 "RD-14-00157"
wdt:P5806 "372890007"
wdt:P592 "CHEMBL80"
wdt:P595 "1676"
"1638"
wdt:P636 Subkutánne podanie
Unutarmišićna injekcija
terapia intravenosa
wdt:P646 "/m/011_yk"
wdt:P652 "36B82AMQ7N"
wdt:P661 "4447644"
wdt:P662 "5284596"
wdt:P665 "C07252"
"D08249"
wdt:P6694 "M0014441"
wdt:P672 "D03.132.577.249.706"
"D03.605.497.750"
"D03.633.400.686.750"
"D04.615.723.795.706"
wdt:P683 "7459"
wdt:P703 Ópíumvalmúi
wdt:P715 "DB01183"
wdt:P8494 "DTXCID703349"
wdt:P8814 "03811921-n"
wdt:P9635 "39"

Inverse relations

[ .. ] → wdt:P4844 → naloxone

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain A Non-interventional, Observational Study for Targinact® Treatment in Patients With Severe Pain. A Pilot Study of the Bioavailability of Nasal Naloxone A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder a Small Dose of Naloxone,Minimize Intrathecal Morphine Side Effects A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers ... show all 277

[ .. ] → wdt:P921 → naloxone

A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Influence Of Low Dose Intrathecal Naloxone On Bupivacaine - Fentanyl Spinal Anaesthesia For Lower Limb Orthopedic Surgery In Elderly Patients The Rhode Island Prescription and Illicit Drug Study
Download as:
RDF/XML JSON-LD Turtle
data from SPARQL endpoint: https://query.wikidata.org/sparql